# Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

> **NCT04666649** · PHASE1 · COMPLETED · sponsor: **University of Maryland, Baltimore** · enrollment: 27 (actual)

## Conditions studied

- Relapsed or Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** Venetoclax and pegcrisantaspase

## Key facts

- **NCT ID:** NCT04666649
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-10
- **Primary completion:** 2024-09-01
- **Final completion:** 2025-05-23
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04666649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04666649, "Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04666649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*